Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Felcisetrag - Takeda/Theravance Biopharma

Drug Profile

Felcisetrag - Takeda/Theravance Biopharma

Alternative Names: TAK-954; TD-8954; THRX-149699

Latest Information Update: 31 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Theravance
  • Developer Takeda; Theravance; Theravance Biopharma
  • Class Antidementias; Benzimidazoles; Carboxylic acids; Gastrokinetics; Piperidines; Small molecules
  • Mechanism of Action Serotonin 4 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic gastroparesis
  • Discontinued Alzheimer's disease; Gastrointestinal motility disorders

Most Recent Events

  • 28 Feb 2023 Takeda terminates its licence for TD 8954 in Australia, Belgium, Czech Republic, Hungary, Netherland, Slovakia, USA
  • 28 Feb 2023 Discontinued - Phase-I for Gastrointestinal motility disorders (In volunteers) in Netherlands (IV)
  • 28 Feb 2023 Discontinued - Phase-I for Gastrointestinal motility disorders in Slovakia, Hungary, Czech Republic (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top